Tapentadol for the Management of Neuropathic Pain from Oxaliplatin Chemotherapy: A Case Report
American Journal of Internal Medicine
Volume 2, Issue 6-1, December 2014, Pages: 1-4
Received: Oct. 18, 2014;
Accepted: Dec. 12, 2014;
Published: Jan. 7, 2015
Views 4043 Downloads 166
Mugabure Bujedo Borja, Department of Anesthesiology, Critical Care and Pain Medicine, Donostia University Hospital, San Sebastian, 20014, Spain; Pain Relief Unit, Chronic Pain Management, Donostia University Hospital, San Sebastian, 20014, Spain
Follow on us
Chronic pain is one of the most important health problems from the XXI century due to its often challenging to address appropriately. Opioids are broad-spectrum analgesics that may be beneficial to alleviate the intense perception of analgesia in patients suffering with pain. They have been one of the most controversial analgesics, in part because of their potential for addiction. Although patients with severe chronic pain may respond to treatment with an opioid analgesic, opioids are often associated with adverse effects that may lead patients to disrupt or discontinue therapy. In addition, opioid drugs alone may not be effective for all types of chronic pain, including neuropathic pain (NP). Opioids or any currently available analgesic will not provide effective analgesia for every patient with chronic NP, but overall, opioids are considered to be a second or third line class of analgesics that may provide reasonable analgesia to some patients with chronic NP. Although opioids may alleviate chronic pain, overall, NP tends to be less opioid responsive than nociceptive pain. Tapentadol prolonged release (PR), a centrally acting analgesic with 2 mechanisms of action, μ-opioid receptor agonism (MOR) and noradrenaline reuptake inhibition (NRI), provides strong and reliable analgesia across a range of indications, including nociceptive, neuropathic, and mixed types of chronic pain, and is associated with an improved tolerability profile relative to classic opioid analgesics. The purpose of this article was to demonstrate clinical efficacy of tapentadol PR in association to pregabalin for the treatment of neuropathic pain from oxaliplatin chemotherapy.
Chronic Pain, Neuropathic Pain, Opioids, Tapentadol, Oxaliplatin
To cite this article
Mugabure Bujedo Borja,
Tapentadol for the Management of Neuropathic Pain from Oxaliplatin Chemotherapy: A Case Report, American Journal of Internal Medicine. Special Issue: Neuropathic Pain.
Vol. 2, No. 6-1,
2014, pp. 1-4.
Bouhassira D, Lantéri-Minet M, Attal N, Laurent B, Touboul C.Prevalence of chronic pain with neuropathic characteristics in the general population. Pain. 2008; 136(3): 380-7.
McNicol ED, Midbari A, Eisenberg E. Opioids for neuropathic pain. Cochrane Database Syst Rev. 2013; 8: CD006146.
Velasco R, Bruna J. Chemotherapy-induced neuropathy: a problem unresolved. Neurology. 2010; 25 (2): 116-131
Saif MW, Reardon J. Management of oxaliplatin-induced peripheral neuropathy. Ther Clin Risk Manag 2005; 1(4): 249–258
Afilalo M, Morlion B. Efficacy of tapentadol ER for managing moderate to severe chronic pain. Pain Physician. 2013; 16 (1): 27-40.
Lange B, Kuperwasser B, Okamoto A, Steup A, Häufel T, Ashworth J, et al. Efficacy and safety of tapentadol extended release for chronic osteoarthritis pain and low back pain. Adv Ther. 2010; 27 (6): 381-99.
Tzschentke TM, Christoph T, Kögel BY. The mu-opioid receptor agonist/noradrenaline reuptake inhibition (MOR-NRI) concept in analgesia: the case of tapentadol. CNS Drugs 2014; 28 (4): 319-29
Sánchez Del Águila MJ, Schenk M, Kern KU, Drost T, Steigerwald I. Practical Considerations for the Use of Tapentadol Prolonged Release for the Management of Severe Chronic Pain. Clin Ther. 2014; S0149-2918 (14) 00445-7. [Epub ahead of print]
Pierce DM, Shipstone E. Pharmacology: tapentadol for neuropathic pain. Am J Hosp Palliat Care. 2012; 29 (8): 663-6
Smith HS. Opioids and neuropathic Pain. Pain Physician. 2012; 15 (3 Suppl): ES 93-110